Skip to main content
SpringerLink
Log in

Antimuscarinic Treatment in Overactive Bladder

Special Considerations in Elderly Patients

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Overactive bladder is a common condition that increases in prevalence in association with age. Antimuscarinic therapy remains the mainstay of pharmacological treatment for the condition, and there is an increasing body of evidence that supports the use of these drugs. Despite this, and because of concerns about associated adverse effects, older people are less likely to receive active treatment for their condition. This review considers some of the factors that need to be taken into account when using these medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29 (1): 4–20.

    PubMed  Google Scholar 

  2. Sexton CC, Coyne KS, Thompson C, et al. Prevalence and effect on health-related quality of life of overactive bladder in older Americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc 2011; 59 (8): 1465–70.

    Article  PubMed  Google Scholar 

  3. Cacioppo JT, Hawkley LC, Norman GJ, et al. Social isolation. Ann NY Acad Sci 2011; 1231 (1): 17–22.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50 (6): 1306–14; discussion 1314–5.

    Article  PubMed  Google Scholar 

  5. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20 (6): 327–36.

    CAS  PubMed  Google Scholar 

  6. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6 (11 Suppl.): S574–9.

    CAS  PubMed  Google Scholar 

  7. Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing 1997; 26 (5): 367–74.

    Article  CAS  PubMed  Google Scholar 

  8. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006; 148 (5): 565–78.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Perry S, Shaw C, Assassa P, et al. An epidemiological study to establish the prevalence of urinary symptoms and felt need in the community: the Leicestershire MRC Incontinence Study. Leicestershire MRC Incontinence Study Team. J Public Health Med 2000; 22 (3): 427–34.

    Article  CAS  PubMed  Google Scholar 

  10. Choo MS, Song C, Kim JH, et al. Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: a prospective trial. J Urol 2005; 174 (1): 201–4.

    Article  CAS  PubMed  Google Scholar 

  11. Kraus SR, Ruiz-Cerda JL, Martire D, et al. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010; 76 (6): 1350–7.

    Article  PubMed  Google Scholar 

  12. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006; 4 (1): 14–24.

    Article  CAS  PubMed  Google Scholar 

  13. Michel MC, Barendrecht MM. Physiological and pathological regulation of the autonomic control of urinary bladder contractility. Pharmacol Ther 2008; 117 (3): 297–312.

    Article  CAS  PubMed  Google Scholar 

  14. Wagg A, Fahey A, Siddiqui E. Persistence with oral antimuscarinics used for the treatment of overactive bladder in different age groups of patients in general practice. Age Ageing 2010; 39 Suppl. 1: i39–40.

    Article  Google Scholar 

  15. Bartus RT. On neurodegenerative diseases, models and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000; 163: 495–529.

    Article  CAS  PubMed  Google Scholar 

  16. Anagnostaras SG, Murphy GG, Hamilton SE, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003; 6 (1): 51–8.

    Article  CAS  PubMed  Google Scholar 

  17. Perry E, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol 2003; 54: 235–8.

    Article  CAS  PubMed  Google Scholar 

  18. Low LF, Anstey KJ, Sachdev P. Use of medications with anticholinergic properties and cognitive function in a young-old community sample. Int J Geriatr Psychiatry 2009; 24: 578–84.

    Article  PubMed  Google Scholar 

  19. Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 2003; 60 (2): 198–203.

    Article  CAS  PubMed  Google Scholar 

  20. Carriere I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 2009; 169 (14): 1317–24.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Fox C, Richardson K, Maidmant ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing Study. J Am Geriatr Soc 2011; 59 (8): 1477–83.

    Article  PubMed  Google Scholar 

  22. Schubert CC, Boustani M, Callahan CM, et al. Comorbidity profile of dementia patients in primary care: are they sicker? J Am Geriatr Soc 2006; 54 (1): 104–9.

    Article  PubMed  Google Scholar 

  23. Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46 (1): 8–13.

    CAS  PubMed  Google Scholar 

  24. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163 (22): 2716–24.

    Article  PubMed  Google Scholar 

  25. Mittal V, Muralee S, Williamson D, et al. Review: delirium in the elderly: a comprehensive review. Am J Alzheimers Dis Other Demen 2011; 26 (2): 97–109.

    Article  PubMed  Google Scholar 

  26. Uusvaara J, Pitkala KH, Kautiainen H, et al. Association of anticholinergic drugs with hospitalization and mortality among older cardiovascular patients: a prospective study. Drugs Aging 2011; 28 (2): 131–8.

    Article  CAS  PubMed  Google Scholar 

  27. Luukkanen MJ, Uusvaara J, Laurila JV, et al. Anticholinergic drugs and their effects on delirium and mortality in the elderly. Dement Geriatr Cogn Dis Extra 2011; 1 (1): 43–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003; 349 (23): 2274–5.

    Article  CAS  PubMed  Google Scholar 

  29. Donnellan CA, Fook L, McDonald P, et al. Oxybutynin and cognitive dysfunction. BMJ 1997; 315 (7119): 1363–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Salvatore S, Serati M, Cardozo L, et al. Cognitive dysfunction with tolterodine use. Am J Obstet Gynecol 2007; 197 (2): e8.

    Article  PubMed  Google Scholar 

  31. Movig KL, Egberts AC, Lenderink AW, et al. Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice. J Am Geriatr Soc 2001; 49 (2): 234–5.

    Article  CAS  PubMed  Google Scholar 

  32. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005; 173 (2): 493–8.

    Article  PubMed  Google Scholar 

  33. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50 (2): 317–26.

    Article  CAS  PubMed  Google Scholar 

  34. Kay GG, Abou-Donia MB, Messer Jr WS, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005; 53 (12): 2195–201.

    Article  PubMed  Google Scholar 

  35. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008 Nov; 62 (11): 1792–800.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Wesnes KA, Edgar C, Tretter RN, et al. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf 2009; 8 (6): 615–26.

    Article  CAS  PubMed  Google Scholar 

  37. Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010; 64 (9): 1294–300.

    Article  CAS  PubMed  Google Scholar 

  38. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001; 41 (6): 636–44.

    Article  CAS  PubMed  Google Scholar 

  39. Herberg K. Alltags-und Verkehrrssicherheit unter Inkontinenz-Medikation. Neue Untersuchungen zum Sicherheitspotential urologischer Anticholinergika. Med Welt 1999; 50: 217–22.

    Google Scholar 

  40. Kay G, Kardiasmenos K, Crook T. Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutynin chloride ER on recent memory in older subjects [abstract]. Proceedings of the 36th meeting of the International Continence Society; 2006 Nov 27–Dec 1; Christchurch.

  41. Rait G, Fletcher A, Smeeth L, et al. Prevalence of cognitive impairment: results from the MRC trial of assessment and management of older people in the community. Age Ageing 2005; 34 (3): 242–8.

    Article  PubMed  Google Scholar 

  42. Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose-response study. Arch Gen Psychiatry 1987; 44 (5): 418–26.

    Article  CAS  PubMed  Google Scholar 

  43. Koller WC. Disturbance of recent memory function in parkinsonian patients on anticholinergic therapy. Cortex 1984; 20 (2): 307–11.

    Article  CAS  PubMed  Google Scholar 

  44. Perlmuter LC, Hakami MK, Hodgson-Harrington C, et al. Decreased cognitive function in aging non-insulin-dependent diabetic patients. Am J Med 1984; 77 (6): 1043–8.

    Article  CAS  PubMed  Google Scholar 

  45. Gaudino EA, Chiaravalloti ND, DeLuca J, et al. A comparison of memory performance in relapsing-remitting, primary progressive and secondary progressive, multiple sclerosis. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14(1): 32–44.

    CAS  PubMed  Google Scholar 

  46. Duka T, Townshend JM, Collier K, et al. Impairment in cognitive functions after multiple detoxifications in alcoholic inpatients. Alcohol Clin Exp Res 2003; 27 (10): 1563–72.

    Article  CAS  PubMed  Google Scholar 

  47. Carnahan RM, Lund BC, Perry PJ, et al. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc 2004; 52 (12): 2082–7.

    Article  PubMed  Google Scholar 

  48. Blazer 2nd DG, Federspiel CF, Ray WA, et al. The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations. J Gerontol 1983; 38 (1): 31–5.

    Article  PubMed  Google Scholar 

  49. Gill S, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005; 165 (7): 808–13.

    Article  PubMed  Google Scholar 

  50. Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf 2011; 10(5): 751–65.

    Article  PubMed  Google Scholar 

  51. Verrier RL, Tan A. Heart rate, autonomic markers, and cardiac mortality. Heart Rhythm 2009; 6 (11 Suppl.): S68–75.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Jouven X, Empana J-P, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352: 1951–8.

    Article  CAS  PubMed  Google Scholar 

  53. Orso F, Baldasseroni S, Maggioni AP. Heart rate in coronary syndromes and heart failure. Prog Cardiovasc Dis 2009; 52 (1): 38–45.

    Article  PubMed  Google Scholar 

  54. Andersson KE, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int 2007; 100 (5): 1007–14.

    CAS  PubMed  Google Scholar 

  55. Andersson KE, Sarawate C, Kahler KH, et al. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 2009 Nov 17.

  56. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20 (6): 392–9.

    CAS  PubMed  Google Scholar 

  57. Schiffers M, Sauermann P, Schurch B, et al. The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects. World J Urol 2010 Oct; 28 (5): 651–6.

    Article  CAS  PubMed  Google Scholar 

  58. Michel MC, Wetterauer U, Vogel M, et al. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. Drug Saf 2008; 31 (6): 505–14.

    Article  CAS  PubMed  Google Scholar 

  59. Hussain RM, Hartigan-Go K, Thomas SH, et al. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 1996; 41 (1): 73–5.

    Article  CAS  PubMed  Google Scholar 

  60. Abrams P, Cardozo L, Chapple C, et al. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 2006; 13 (6): 692–8.

    Article  CAS  PubMed  Google Scholar 

  61. Olshansky B, Ebinger U, Brum J, et al. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or =50 years. J Cardiovasc Pharmacol Ther 2008; 13 (4): 241–51.

    Article  CAS  PubMed  Google Scholar 

  62. Pietzko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin pharmacol 1994; 47 (4): 337–43.

    Article  CAS  PubMed  Google Scholar 

  63. Alzayer R, Hughes J, Parsons R, et al. Comparison of risk of neurovascular and cardiovascular side effects between tiotropium and other anticholinergic agents. Qual Prim Care 2010; 18(3): 189–99.

    PubMed  Google Scholar 

  64. Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol 2011; 72 (2): 186–96.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Hopcraft MS, Tan C. Xerostomia: an update for clinicians. Aust Dent J 2010; 55 (3): 238–44; quiz 353.

    Article  CAS  PubMed  Google Scholar 

  66. Pajukoski H, Meurman JH, Halonen P, et al. Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92 (6): 641–9.

    Article  CAS  PubMed  Google Scholar 

  67. Gist RF, O’Loughlin KT. Warning label information on medications associated with xerostomia (dry mouth). 2011 Apr 25 [online]. Available from URL: http://www.ada.org/sections/newsAndEvents/pdfs/ltr_dry_mouth_110427.pdf [Accessed 2012 May 14].

  68. Kessler TM, Bachmann LM, Minder C, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One 2011;6(2):e16718.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. Herschorn S, Pommerville P, Stothers L, et al. Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (</= 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. Curr Med Res Opin 2011; 27 (2): 375–82.

    Article  CAS  PubMed  Google Scholar 

  70. Rome III diagnostic criteria for functional gastrointestinal disorders: appendix A. Raleigh (NC): Rome Foundation, Inc., 2006 [online]. Available from URL: http://www.romecriteria.org/assets/pdf/19_RomeIII_apA_885-898.pdf [Accessed 2012 May 16].

  71. Coyne KS, Cash B, Kopp Z, et al. The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder. BJU Int 2011; 107 (2): 254–61.

    Article  PubMed  Google Scholar 

  72. Donald IP, Smith RG, Cruikshank JG, et al. A study of constipation in the elderly living at home. Gerontology 1985; 31 (2): 112–8.

    Article  CAS  PubMed  Google Scholar 

  73. Kinnumen O. Study of constipation in a geriatric hospital, day hospital, old people’s home and at home. Aging (Milano) 1991; 3 (2): 161–70.

    Google Scholar 

  74. Harari D, Gurwitz JH, Avorn J, et al. How do older persons define constipation? Implications for therapeutic management. J Gen Int Med 1997; 12 (1): 63–6.

    Article  CAS  Google Scholar 

  75. Meek PD, Evang SD, Tadrous M, et al. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci 2011; 56 (1): 7–18.

    Article  CAS  PubMed  Google Scholar 

  76. Arnett 3rd RH, Blank LA, Brown AP, et al. National health expenditures, 1988. Office of National Cost Estimates. Health Care Financ Rev 1990; 11 (4): 1–41.

    Google Scholar 

  77. Gupta S, Rappaport HM, Bennett LT. Inappropriate drug prescribing and related outcomes for elderly Medicaid beneficiaries residing in nursing homes. Clin Ther 1996; 18 (1): 183–96.

    Article  CAS  PubMed  Google Scholar 

  78. Golden AG, Preston RA, Barnett SD, et al. Inappropriate medication prescribing in homebound older adults. J Am Geriatr Soc 1999; 47 (8): 948–53.

    CAS  PubMed  Google Scholar 

  79. O’Connor K, O’Mahony D. Drugs and ageing. In: Liston R, Mulkerrin EC, editors. Medicine for older patients: cases and practice. Dublin: Eireann Healthcare Publications, 2003.

    Google Scholar 

  80. Royal College of Physicians. Medication for older people. London: Royal College of Physicians, 1997.

    Google Scholar 

  81. Kennerfalk A, Ruigomez A, Wallander MA, et al. Geriatric drug therapy and healthcare utilization in the United Kingdom. Ann Pharmacother 2002; 36 (5): 797–803.

    Article  PubMed  Google Scholar 

  82. Witte LP, Mulder WM, de la Rosette JJ, et al. Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? Curr Opin Urol 2009; 19 (1): 13–9.

    Article  PubMed  Google Scholar 

  83. Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. Ann Pharmacother 1999; 33 (11): 1173–6.

    Article  CAS  PubMed  Google Scholar 

  84. Fillit HM, Rockwood K, Woodhouse K. Brocklehurst’s textbook of geriatric medicine and gerontology. 7th ed. Philadelphia (PA): Saunders/Elsevier 2010.

    Google Scholar 

  85. Shimp LA, Wells TJ, Brink CA, et al. Relationship between drug use and urinary incontinence in elderly women. Drug Intell Clin Pharm 1988; 22 (10): 786–7.

    CAS  PubMed  Google Scholar 

  86. Alling Moller L, Lose G, Jorgensen T. Risk factors for lower urinary tract symptoms in women 40 to 60 years of age. Obstet Gynecol 2000; 96 (3): 446–51.

    Article  CAS  PubMed  Google Scholar 

  87. Van Oyen H, Van Oyen P. Urinary incontinence in Belgium: prevalence, correlates and psychosocial consequences. Acta Clin Belg 2002; 57 (4): 207–18.

    Article  PubMed  Google Scholar 

  88. Ruby CM, Hanlon JT, Boudreau RM, et al. The effect of medication use on urinary incontinence in community-dwelling elderly women. J Am Geriatr Soc 2010; 58 (9): 1715–20.

    Article  PubMed Central  PubMed  Google Scholar 

  89. Landi F, Cesari M, Russo A, et al. Benzodiazepines and the risk of urinary incontinence in frail older persons living in the community. Clin Pharmacol Ther 2002; 72 (6): 729–34.

    Article  CAS  PubMed  Google Scholar 

  90. Movig KL, Leufkens HG, Belitser SV, et al. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 2002; 11 (4): 271–9.

    Article  CAS  PubMed  Google Scholar 

  91. Hashimoto M, Imamura T, Tanimukai S, et al. Urinary incontinence: an unrecognised adverse effect with donepezil. Lancet 2000; 356 (9229): 568.

    Article  CAS  PubMed  Google Scholar 

  92. Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001; 97 (1): 116–20.

    Article  CAS  PubMed  Google Scholar 

  93. Starr J. Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer’s disease. J Am Geriatr Soc 2007; 55: 800–1.

    Article  PubMed  Google Scholar 

  94. Siegler EL, Reidenberg M. Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin Pharmacol Ther 2004; 75 (5): 484–8.

    Article  CAS  PubMed  Google Scholar 

  95. Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005; 165 (7): 808–13.

    Article  PubMed  Google Scholar 

  96. Sink K, Thomas 3rd J, Xu H, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 2008; 56: 847–53.

    Article  PubMed  Google Scholar 

  97. Isik AT, Celik T, Bozoglu E, et al. Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging 2009; 13 (8): 672–6.

    Article  CAS  PubMed  Google Scholar 

  98. Sakakibara R, Ogata T, Uchiyama T, et al. How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist. J Am Geriatr Soc 2009; 57 (8): 1515–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The author has received honoraria for research, speaker fees or consultancy fees from Pfizer, Astellas, Watson Pharma and Orion Pharma, all of whom are involved with the manufacture and marketing of medications for OAB; and SCA, who are a major manufacturer of continence products. The author declares he has no conflicts of interest directly related to the production of this article and received no funding to assist with the preparation of the article.

Author information

Authors and Affiliations

  1. Division of Geriatric Medicine, Department of Medicine, University of Alberta, 1-116 Clinical Sciences Building, 11350-83 Avenue, Edmonton T6G, Alberta, Canada

    Adrian S. Wagg (Professor of Healthy Ageing)

Authors
  1. Adrian S. Wagg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adrian S. Wagg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wagg, A.S. Antimuscarinic Treatment in Overactive Bladder. Drugs Aging 29, 539–548 (2012). https://doi.org/10.1007/BF03262272

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262272

Keywords

Search

Navigation